Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919160 | 0.85 | GAA (0.36) | GAACYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL29508220 | 0.83 | KMT2A (0.36) | KMT2A | |
| SCHEMBL4919154 | 0.82 | GAA (0.32) | GAAALDH1A1KMT2A | |
| SCHEMBL27292832 | 0.81 | GAA (0.34) | GAACYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL21431166 | 0.80 | HDAC6 (0.38) | HPGDCYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL21431255 | 0.80 | HDAC6 (0.38) | HPGDCYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL12191613 | 0.80 | SMN1; SMN2 (0.33) | GAAHPGDALDH1A1KMT2AHDAC6 | |
| SCHEMBL19731703 | 0.80 | HPGD (0.38) | GAAHPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18349841 | 0.79 | HDAC1 (0.35) | GAAALDH1A1KMT2AHDAC6 | |
| SCHEMBL12258958 | 0.79 | OPRM1 (0.39) | CYP1A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025015097-A1 | DNA-BASED PROTEOLYSIS TARGETING CHIMERA (SDTAC) AND METHODS OF THEIR USE FOR TREATING DISEASES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015018-A1 | CONDITIONAL PROTEOLYSIS GENE SILENCING TARGETING CHIMERA AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-111295444-B | Polynomial coding for oligonucleotide-directed combinatorial chemistry | 哈斯达克科学公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240264142-A1 | MOLECULAR DETECTION AND COUNTING USING NANOPORES | ROCHE SEQUENCING SOLUTIONS INC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-3617314-B1 | OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF | KYOWA KIRIN CO LTD (JP) | 2023-02-15 | — | — | EP | disclosed |
| CN-109312492-B | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220154179-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINITORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | HAYSTACK SCIENCES CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220145362-A1 | METHODS AND SYSTEMS FOR PROCESSING OR ANALYZING OLIGONUCLEOTIDE ENCODED MOLECULES | HAYSTACK SCIENCES CORPORATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20190284619-A1 | IN SITU PROBE INVERSION PROCESS FOR CONTSTRUCTING PROBE ARRAYS | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2019-09-19 | — | — | US | disclosed |
| WO-2018102660-A1 | IN SITU PROBE INVERSION PROCESS FOR CONSTRUCTING PROBE ARRAYS | CENTRILLION TECHNOLOGIES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284619-A1 | IN SITU PROBE INVERSION PROCESS FOR CONTSTRUCTING PROBE ARRAYS | CPSF6, INF2, TENT4A | GAA 2874/4885HPGD 4674/4885CYP3A4 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.